Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma

Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma
Proactive

Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner chats to Proactive’s Andrew Scott about recent news from its GBM AGILE pivotal study for glioblastoma. Dr Garner also discusses data received from its brain metastases study and the commercial prospects when it comes to brain metastases.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK